Combination treatment for recurrent ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two drugs, RIF (a form of arsenic) and anlotinib (a targeted therapy), for women whose ovarian cancer has returned and stopped responding to standard platinum chemotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer that has come back within 6 months of your last platinum chemotherapy.
- You are able to take care of yourself (ECOG 0 or 1) and expected to live at least 4 months.
- Your blood counts, liver, kidney, and heart function are within acceptable levels.
- You can take pills by mouth.
- You have not had certain treatments (like arsenic or anlotinib) before, and you are not pregnant or breastfeeding.
- You do not have serious bleeding, blood clots, uncontrolled high blood pressure, or other major health issues listed in the trial rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial tests a new drug (HS-20089) combined with another drug (bevacizumab) for women whose ovarian cancer has returned after responding to platinum-based chemotherapy. The goal is to see if this combination helps control the cancer better than standard options.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
Hear when a new Platinum-resistant Ovarian Cancer (PROC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.